Composition and Method for Diagnosis and Immunotherapy of Lung Cancer

Abstract

The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.

What is claimed is: 
     
         1 . A composition for the treatment of lung cancer comprising:
 an isolated antigen presenting cell that has been loaded to present at least one SP17, AKAP-4, or PTTG1 tumor-associated antigens and that generates a cytotoxic T lymphocyte specific immune response to the at least one of SP17, AKAP-4, or PTTG1, respectively, expressed by one or more lung cancer cells.   
     
     
         2 . The composition of  claim 1 , wherein the antigen presenting cell is a dendritic cell. 
     
     
         3 . The composition of  claim 1 , wherein the antigen presenting cell is an autologous dendritic cell. 
     
     
         4 . The composition of  claim 1 , wherein the composition further comprises at least one of NYESO-1, XAGE-1, ADAM29 and MAGEC1 antigens loaded into the antigen presenting cell. 
     
     
         5 . The composition of  claim 1 , wherein the composition comprises a nucleotide sequence that encodes for the recombinant SP17, AKAP-4, or PTTG1 tumor-associated antigen and the recombinant SP17, AKAP-4, or PTTG1 is expressed in the antigen presenting cell. 
     
     
         6 . A method for identifying a human subject suspected of having subject or at least at risk of developing lung cancer comprising the steps of:
 obtaining a sample from the subject; and   determining the presence or absence of a specific immunoglobulin in the sample specific for at least one of anti-SP17, AKAP-4, or PTTG1, wherein the presence of the at least one of anti-SP17, AKAP-4, or PTTG1 specific immunoglobulin in the sample indicating the subject is afflicted with or at least at risk of developing lung cancer.   
     
     
         7 . A method for the determination of the tumor marker profile of an individual suffering from cancer comprising:
 obtaining a sample of bodily fluids from the individual;   contacting the sample of bodily fluids from the individual with at least one of SP17, AKAP-4, or PTTG1 tumor-associated antigen;   determining the presence or absence of a complex of the at least one of SP17, AKAP-4, or PTTG1 tumor-associated antigen bound to one or more autoantibodies present in the sample of bodily fluids, wherein the one or more autoantibodies being immunologically specific to the at least one of SP17, AKAP-4, or PTTG1 tumor-associated antigen; wherein the presence of the complex provides the tumor marker profile of the individual, and wherein the tumor marker profile is determined as an indication of the course of disease; and   providing the individual with an antigen presenting cell or a cytotoxic T cell specific to the at least one of SP17, AKAP-4, or PTTG1.   
     
     
         8 . The method of  claim 7 , wherein the presence of the complex indicates the detection of cancer. 
     
     
         9 . The method of  claim 7 , wherein the cancer is lung cancer. 
     
     
         10 . An immunotherapy composition for the treatment of cancer comprising at least one of an SP17, AKAP-4, or PTTG1 tumor-associated antigen capable of generating an SP17, AKAP-4, or PTTG1 specific cytotoxic T lymphocyte specific for one or more lung cancer cells. 
     
     
         11 . The immunotherapy composition of  claim 10 , further comprising at least one antigen presenting cell. 
     
     
         12 . The immunotherapy composition of  claim 11 , wherein the antigen presenting cell is a dendritic cell. 
     
     
         13 . The immunotherapy composition according to  claim 10 , wherein the at least one antigen presenting cell is a pulsed or loaded with the peptide or an expression construct encoding the SP17, AKAP-4, or PTTG1 tumor-associated antigen. 
     
     
         14 . The immunotherapy composition according to  claim 10 , wherein the at least one of an SP17, AKAP-4, or PTTG1 tumor-associated antigen is isolated from a non-small cell lung carcinoma. 
     
     
         15 . A method for detecting lung cancer in a subject comprising the steps of:
 obtaining a sample from the subject;   determining the presence or absence of SP17, AKAP-4, or PTTG1 in the sample, wherein the presence of SP17, AKAP-4, or PTTG1 in the sample indicates the subject is afflicted with or at least at risk for developing lung cancer; and   providing the individual with an antigen presenting cell or a cytotoxic T cell specific to the at least one of SP17, AKAP-4, or PTTG1.   
     
     
         16 . The method of  claim 15 , wherein the sample is a blood sample. 
     
     
         17 . A composition comprising a nucleic acid vector that expressed an immunostimulatory antigen, wherein the antigen comprises the nucleotide sequence coding for at least one of an SP17, AKAP-4, or PTTG1 lung cancer-associated antigen. 
     
     
         18 . The composition of  claim 17 , wherein the antigen is a peptide antigen. 
     
     
         19 . A method for the treatment of cancer comprising the steps of:
 administering to a mammal in need thereof a synergistic, therapeutically effective amount of a lung cancer antigen, in addition to at least one of diluents, vehicles, excipients, or inactive ingredients;   generating a specific cytotoxic T lymphocytes (CTL) from the lung cancer antigen; and   targeting one or more tumor cells with the specific cytotoxic T lymphocytes.   
     
     
         20 . The method of  claim 19 , wherein the lung cancer antigen is SP17, AKAP-4, or PTTG1.